Market News / Story
Caribou falls as analysts downgrade on plans to explore strategic alternatives
Seeking Alpha ·
Seeking Alpha reports: Shares of Caribou Biosciences reached an all-time low on Wednesday after the cell therapy developer announced plans to explore strategic alternatives, prompting RBC Capital Markets and Leerink Partners to downgrade the biotech. In a statement on Tuesday, the Berkeley, California-based company announced workforce and cost reductions as well as plans to halt allogeneic CAR-T programs, vispa-cel and CB-011, in line with the decision. The move came at a time when the…